TRPM7 and glioblastoma: However, while the TRPM7 activator naltriben appears to enhance the invasive behaviour of glioblastoma multiforme cell line U87 [180] and TRPM7-selective inhibitors (Waixenicin A) that have been described [181,182], it remains to be determined whether pharmacological blockade of TRPM7 has any cancer-specific therapeutic potential in the clinic.